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Abstract. Previous studies have shown that the cholinergic
system plays a pivotal rule in small cell lung cancer (SCLC)
cell growth through an autocrine loop that activates the nicotinic
cholinergic receptor, which together with the activation of this
receptor by nicotine links SCLC evolution with tobacco use.
Non-small cell lung cancer (NSCLC) is the most common form
of lung cancer and is also linked to tobacco use. Here we
describe the presence of molecules of the cholinergic system in
NSCLC samples and cell lines and investigate the implications
of the cholinergic system in cell growth regulation. Cholino-
acetyltransferase (ChAT), vesicular acetylcholine transporter
(VAChT) and acetylcholinesterase (AChE) were observed in
NSCLC tumor biopsies and in NSCLC cell lines. Polymeric
alkylpyridinium salts (poly-APS) are AChE inhibitors isolated
from the crude extract of the marine sponge, Reniera sarai.
These metabolites were characterized as a mixture of two
polymers of 3-octylpyridinium, including 29 and 99 monomeric
units. Exposure of normal lung fibroblast and NSCLC cell lines
to poly-APS revealed a selective cytotoxicity for cancer cells
as compared to the normal fibroblast cell lines. FACS analysis
indicated poly-APS induced apoptosis in NSCLC cells but
not in normal lymphocytes. Non-toxic doses of poly-APS
also potently reduced NSCLC cell-cell adhesion in suspension
cultures. The limited toxicity of poly-APS on normal cells was
confirmed by injection in the caudal vein of mice. No overt
effects on health parameters, such as weight gain and physical
behavior, were observed, and histological analysis of major
organs did not reveal differences between the treated animals
as compared to controls. These data demonstrate that NSCLC
cells express cholinergic molecules that may be involved in
cell growth regulation and that the cholinesterase inhibitor,
poly-APS, shows selective toxicity toward NSCLC cells while
having no apparent toxicity towards normal cells and tissue
in vitro and in vivo.
Introduction
Lung cancer remains the leading cause of mortality due to
cancer in the Western world. Of the two major types of lung
cancer, approximately 75-80% are non-small cell lung cancer
(NSCLC) with the remaining 20-25% being small cell lung
cancer (SCLC). SCLC, a rapidly disseminating and metastatic
cancer (1), is almost invariably linked to tobacco use (2). The
effects of tobacco exposure are linked to the presence of
nicotinic receptors, part of the cholinergic system, on SCLC
cells (3). Small cell lung carcinomas express receptors for
acetylcholine (ACh), and their stimulation by nicotine or other
cholinergic agonists stimulates cell growth through activation
of nicotinic cholinergic receptors (nAChRs) and/or muscarinic
cholinergic receptors (mAChRs) (4-6). Cholinergic autocrine
loops may also regulate SCLC cell growth (7), as these cells
express cholino-acetyltransferase (ChAT), the vesicular ACh
transporter (VAChT) and cholinergic receptors. 
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Non-small cell lung cancer (NSCLC) is currently the most
common cause of cancer mortality and morbidity extending
beyond industrialized countries (8). Although NSCLC occurs
in non-smokers, tobacco smoking is clearly a key etiological
factor responsible for the majority of these cancers (8). The
correlation between tobacco use and NSCLC incidence has
been thoroughly demonstrated (9-11) but there is no direct
evidence that the growth of this tumor is regulated by nicotine
activation of cholinergic receptors. 
The observation that ACh receptors (AChRs) can regulate
lung cancer cell growth suggests that the cholinergic system
may be a potential pharmaceutical target. Efficient inhibitors
of acetylcholinesterase (AChE) have been isolated from the
Adriatic marine sponge, Reniera sarai (12). These compounds
were identified as polymeric 3-octylpyridinium salts (poly-
APS) that exist as a mixture of two polymers with molecular
weights of 5600 and 18900 Da. Poly-APS form part of a
defense mechanism of the sponge against biofouling by other
marine organisms. In laboratory conditions, they show an
effective non-toxic anti-settlement effect on barnacles of
Balanus amphitrite (13). In general, pyridinium derivates
are known as AChE inhibitors acting either as competitive
inhibitors binding on the catalytic anionic site at the bottom
of the enzyme gorge, or as non-competitive inhibitors binding
at the peripheral anionic site at the rime of the enzyme gorge,
slowing or preventing the entrance of acetylcholine into the
gorge (14,15). In contrast, inhibition of AChE by a highly
polymeric poly-APS proceeds by a rather complex and unusual
pattern (16), ending in an irreversible inhibition of the enzyme
(17). In addition to AChE-inhibition, poly-APS also exert
haemolytic, and moderate and variable cytotoxic activity on
different cell lines (16). 
These observations led us to investigate the expression of
the cholinergic system in NSCLC cells, and to then test the
potential of poly-APS as a chemotherapy agent in lung cancer
models. Here we show that NSCLC cell lines and cells isolated
from primary NSCLC all express cholino-acetyltransferase
(ChAT), the vesicular ACh transporter (VAChT) and acetyl-
cholinesterase (AChE). Further, we show that the AChE
inhibitors, poly-APS, have selective toxicity on tumor cells
with log lower toxicity towards normal lung fibroblasts. These
effects, combined with the fact that poly-APS are reasonably
well-tolerated in vivo in animal models, indicate that these
compounds may be considered as alternative inhibitors of lung
cancer with lower systemic toxicity.
Materials and methods
Poly-APS. Poly-APS were isolated from Reniera sarai sponge
according to previously described procedures (12). Stock
concentrations of 1 mg/ml in distilled water were prepared.
Based on activity, these stocks were stable at 4˚C for at least
several months. Since poly-APS compounds are a mixture of
2 polymers, the molar concentration calculations were estimated
assuming a 1:1 ratio between them, giving a molecular weight
of 12200 g/mol.
Surgical samples and cell lines. Selected surgical samples
were obtained in an ethically compatible manner (information,
anonymity, allowance etc., according to the European laws
of Bioethics) from affected patients. NSCLC samples were
cut for the classification according to the International
Classification of Diseases for Oncology (ICD-O). Some
samples were used for Western blot analysis as described
below.
A549, Ca-Lu-1 and Sk-Lu-1 adenocarcinoma cell lines
were grown in RPMI-1640 supplemented with 10% non-heat
inactivated FBS, L-glutamine and appropriate antibiotics.
MRC-5 normal lung fibroblast primary cell line was grown in
DMEM supplemented with 10% FBS, L-glutamine, antibiotics
and non-essential amino acids (Celbio).
Lymphocytes were obtained from healthy donor buffy-coats
after Ficoll (Lympholyte-H, Cedarlane) separation and were
cultured in RPMI-1640 supplemented with 10% non-heat
inactivated FBS, L-glutamine and appropriate antibiotics. 
Methods
Immunohistochemical analysis. Slides bearing A549 cultured
cells were fixed with cold 4% paraformaldehyde (PFA) in
phosphate-buffered saline (PBS), thoroughly rinsed and
processed for immunohistochemical analysis against cholin-
ergic molecules. Slides were incubated for 30 min at room
temperature with the primary antibodies. Polyclonal anti-ChAT
(Chemicon International) that was used to detect the bio-
synthetic enzyme for ACh. Anti-AChE polyclonal antibodies
(Santa Cruz Biotechnology) were used to identify the lytic
enzyme for ACh. Anti-VAChT polyclonal antibodies (Santa
Cruz Biotechnology) were used to identify the vesicular trans-
porter of ACh. Primary antibodies were diluted 1:250 in
Tris-HCl 0.05 M (pH 7.4) containing 1% BSA. After incu-
bation, samples were rinsed three times with Tris-buffered
saline and 0.1% Tween-20 (TBST) and incubated for 30 min at
room temperature with peroxidase-labeled polymer conjugated
to goat anti-mouse or anti-rabbit immunoglobulins (EnVision+
System, Peroxidase; Dako Corporation). The provided
substrate-chromogen was applied to cells and incubated for
5-10 min. Nuclei counterstaining was obtained with Mayer's
hematoxylin (Bio-Optica) incubation. Stained slides were
mounted in glycerol gel mounting media (Dako). 
Western blot analysis. NSCLC samples, A549 and SK-Lu-1
cells were homogenized in buffer containing 0.1% Tween and
5 μl/ml of protease inhibitor cocktail (Sigma). The protein
extracts were quantified with a Bradford-based colorimetric
method (Bio-Rad). Total protein homogenate (20-30 μg)
was run into a 10% SDS-PAGE and then transferred to a
nitrocellulose membrane. Non-specific binding sites were
blocked with blocking buffer containing TBST with 5% non-fat
milk powder for 45 min at room temperature, and the blot
was incubated with specific antibodies in blocking buffer
with rabbit polyclonal anti-AChE (Santa Cruz Biotechnology),
rabbit polyclonal anti-VAChT (Santa Cruz Biotechnology)
rabbit polyclonal anti-ChAT (Chemicon International) at room
temperature overnight. After washing, the blot was incubated
with the appropriate secondary antibodies (Santa Cruz, Bio-
technology) for 1 h and 30 min at room temperature. After
extensive washing, detection was performed directly on the
membrane using one-step NBT-BCIP solution (Pierce). All
experiments were performed at least three times, obtaining
very similar results.
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Cell proliferation assay. Poly-APS toxicity was tested using
crystal violet staining. All of the experiments for each drug
were performed at least three times with a minimum of 6
replicates per data point per experiment. Cells were plated with
an 8-channel pipette at 1500 cells/well in 96-well plates. Poly-
APS was added to plates 24 h after plating and experiments
were carried out for 48, 72 and 96 h respectively, in a range
of concentration of 500 nM to 1.28 pM. 
Organ toxicity. To examine for organ toxicity, C57BL/6N mice
(n=30, 20±2 g) (Charles River Laboratories) were divided
into five groups (6 per group) and injected with poly-APS
through the caudal vein at 0.5 mg/kg and at 1 mg/kg with
Heparin-sulphate (Heparin, Sigma-Italy, 10 U/100 g body
weight). Animals were sacrificed at specific time intervals
(t=0; 30 min, 1 h, 2 h, 24 h) and the principal organs were
taken immediately for routine histological analysis. The
animals were treated according to the institute's animal care
for the protection of vertebrates used for experimental and
other specific purposes.
3D cultures. A549 cells (2x106) were plated in round-bottom
bacterial 96-well plates and cultured in RPMI-1640 containing
20% of methyl-cellulose (stock 0.6 g/50 ml) to induce growth
suspension, with untreated cells forming spheroids. The cells
were treated with 800 pM of poly-APS for 24 h and analyzed
morphologically with light and confocal microscopy.
Lectin staining. 3D A549 cultures were rinsed in PBS and
placed in a humid chamber. To prevent internalization of the
lectins the cells were treated with 0.02% sodium azide in PBS.
Cells were then treated with wheat germ agglutinin (WGA)
conjugated with fluorescein (F1TC) and concanavalin A
(ConA) conjugated with rhodamine (TR1TC) diluted 1:10 for
30 min at room temperature, fixed with 4% formalin for 30 min,
and mounted using glycerol-saline for viewing with a confocal
microscope.
Annexin-V staining. Following previously described protocols
(18), the A549 adenocarcinoma cell line and normal (activated
and non-activated) lymphocytes were treated for 24 h with
451 nM of poly-APS and analyzed using a FACSort cytometer
(Becton-Dickinson).
Statistical analysis. Data obtained from cytotoxicity test were
statistically analyzed with Primer Program Version 1.0. The
statistical analysis was performed by ANOVA followed by
Student's-Newman-Keuls tests for multiple comparison and
significance between differences was established at P<0.05.
Results
Presence of cholinergic molecules in NSCLC. Previous studies
have shown that molecules of the cholinergic system are
expressed on and influence the growth of SCLC, and suggested
a role for nicotine as a promoting agent in tobacco-driven
lung cancer development. We therefore investigated whether
this system is present and active in NSCLC. Western blot
analyses demonstrated expression of the components of the
cholinergic system on NSCLC tumor cell lines in vitro and
in NSCLC tumor biopsies in vivo (Fig. 1). Enzymes involved
in production of the transmitter were strongly expressed in
both cell ines and tumor biopsy samples, including cholino-
acetyltransferase (ChAT), and vesicular ACh transporter
(VAChT). Both cell lines and tumor biopsy samples showed
expression of the lytic enzyme of ACh, acetylcholine-esterase
(AChE) (Fig. 1). While both cell lines and tumor biopsies
showed strong expression of the G-protein coupled muscarinic
M1 class receptor, the cell lines showed expression of the M2
class muscarinic receptor, which regulates ion channels,
whereas the tumor biopsies did not (Fig. 1). In contrast, only
the tumor biopsies showed expression of the ·7 nicotinic
receptor, while the cultured cell lines were negative. The reason
for these differences is not clear, but may reflect adaptation
to culture conditions on one hand and a promotion effect by
nicotine in lung cancer on the other.
In cultured A549 cells, the ChAT enzyme was mainly
localized in the cytoplasm, showing an intense activity of
synthesis of the enzyme, diffusing towards the periphery. The
staining extended to the membrane only in some focal points
of cell-to-cell contact (Fig. 2), in particular areas of cell-to-
cell adhesion were immunoreactive. The ACh transporters
VAChT in A549 cells immuno-localized in vesicles that
were mainly distributed on the cytoplasmatic side of the cell
surface, suggesting that ACh is actively transported outside
the cell (Fig. 2). Taken together, these data demonstrate
autonomous synthesis and release of acetylcholine by NSCLC
cells. 
Immunocytochemistry with specific AChE polyclonal
antibodies demonstrated prominent intracellular immuno-
reactivity in A549 cells. The anti-AChE staining pattern
was consistent with vesicular localization; in some cases,
the enzyme is localized in the cytosolic surface of the cell
membrane (Fig. 2). Expression of the ACh lytic enzyme
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Figure 1. Western blot analyses of the presence of the components of the
cholinergic system in A549 and SK-LU-1 NSCLC cell lines and in human
tumor biopsies (numbered 1-6). ChAT, cholino-acetyltransferase; VAChT,
vesicular ACh transporter; AChE, acetylcholine-esterase; M1R, muscarinic
M1 receptor; M2R, muscarinic M2 receptor; ·7R, ·7 nicotinic receptor.
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indicates tight regulation of ACh activity in NSCLC. The
class 1 muscarinic receptors were clearly localized on cultured
A549 cells (Fig. 2), while reactivity for the class 2 muscarinic
receptors was weaker and for the ·7 nicotinic receptor it was
absent (not shown).
Interruption of cholinergic regulation induces cytostasis/
cytotoxicity. Since molecules that pertain to the cholinergic
system are expressed in both NSCLC lines and tumor tissues,
we investigated the effects of altering cholinergic homeostasis
in cell growth and viability in vitro. We used poly-APS as an
AChE inhibitor to induce accumulation of ACh in vitro in
normal lung fibroblasts, NSCLC cell lines and primary NSCLC
cell cultures. The dose- and time-dependent responses to poly-
APS were determined using the crystal violet assay. Poly-APS
selectively inhibited tumor cell growth in a concentration-
dependent manner (Fig. 3). While MRC5 lung fibroblasts did
not show alterations in growth until high concentrations of
poly-APS were used, at which point cell viability rapidly
declined, showing an EC50s of 50.27 nM (72 h) and 50.66 nM
(96 h) . In contrast, the A549 and CaLu NSCLC cell lines
showed higher sensitivity to poly-APS, with EC50s one log
lower on the order of 4.41-6.9 nM. Finally, primary cultures
of NSCLC cells were exquisitely sensitive to the cell killing
activity of poly-APS, with EC50s of 0.86 and 0.36 nM, fully
two logs lower than that of normal lung fibroblasts. While
the Hill slopes were relatively steep for MRC5 fibroblasts,
suggesting a toxicity threshold, those for the primary cells
were relatively shallow, indicating an alteration in biological
signaling that leads to cell death by apoptosis. These data
showed that poly-APS inhibition of AChE led to potent growth
inhibition and cell death in NSCLC cells but had more limited
effects on normal cells. 
Quantification of apoptosis in normal and tumor cells. The
activation of apoptosis by poly-APS in normal and tumor cells
was quantitatively analyzed by FITC-labeled annexin V/
propidium iodide (PI) uptake analysis with fluorescent cyto-
metry. In the early stages of apoptosis, membrane phosphatidyl-
serine (PS) is translocated from the inner to the outer plasma
membrane, exposing PS to the binding of annexin V (18). PI
stains nucleic acids and does not enter into viable cells, thus
PI-positive cells are indicative of an apoptotic or necrotic
event. Vehicle-treated normal leukocytes or A549 tumor cells
(controls) were primarily annexin V-FITC and PI-negative,
indicating that the cells were viable and not apoptotic (Fig. 4).
Freshly isolated normal leukocytes were used to verify the
relatively low toxicity of poly-APS for normal cells. Even
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Figure 2. Immunohistochemical analysis to detect the localization of
cholinergic components in A549 cells in vitro. ChAT, cholino-acetyl-
transferase; VAChT, vesicular ACh transporter; AChE, acetylcholine-
esterase; M1R, muscarinic M1 receptor; M2R, muscarinic M2 receptor.
Figure 3. Selective dose-dependent inhibition of tumor cell proliferation
in vitro by poly-APS. MRC5, the MRC5 human primary lung fibroblast
line. A549, A549 NSCLC cells. Calu-1, Calu-1 NSCLC cells. Primary, a
primary NSCLC cell culture. Tests were carried out for 48 and 72 h at the
indicated concentrations. Bars indicate means ± SEM.
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after treatment with relatively high (450 nM) levels of poly-
APS for 24 h, normal leukocytes showed low levels of apop-
tosis only slightly above those of untreated cells (Fig. 4).
Leukocytes activated with Phaseolus vulgaris Leucoagglutinin
(PHA-H) showed only a slight increase in sensitivity to
apoptosis (data not shown), gating on CD3 indicated that
most of these few apoptotic cells were CD3-positive. In
contrast, and in agreement with in vitro studies, a strong
increase in annexin V binding was observed in A549 cells after
exposure to poly-APS, with nearly 60% of the cells in apoptosis
(Fig. 4). Again, primary NSCLC cells showed even higher
sensitivity to poly-APS, with ~80% of the cells in apoptosis.
These data indicate that lung cancer cells are particularly
sensitive to apoptosis induction upon interference with the
cholinergic system by poly-APS, while control cells were not. 
Effect of low poly-APS doses on cell-cell interatins in vitro.
When grown in suspension culture, NSCLC cell lines formed
three-dimensional spheroids with tight cell-cell adhesion. When
these cultures were treated with low, sub-toxic doses of poly-
APS, a remarkable change in morphology was observed,
with inhibition of the ability of the cells to form spheroids,
the cells remained scattered on the bottom of the wells
(Fig. 5). Malignant transformation has been associated with
abnormal glycosylation (19), which is functionally implicated
in the malignant behavior of cancer cells. By staining with
fluorescently labeled lectins, we observed a reduction of
lectin staining associated with a loss of cell-to-cell adhesion
(Fig. 5), suggesting that cholinergic system alterations induced
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Figure 4. Induction of apoptosis in A549 NSCLC lines, primary NSCLC
cells and in normal lymphocytes (as indicated) by analysis of Annexin V by
flow cytometry. Control (a, c and e) and poly-APS-treated cells (b, d and f). a
and b, A549 cells; c and d, primary cells; e and f, freashly isolated CD3+
lymphocytes. g, The table indicates the percentage of gated cells in the single
cell populations. Figure 5. Three-dimensional spheroids formed by A549 cells either
untreated or sub-lethal poly-APS treated. WGA and ConA lectin staining
and merge of both on control and treated cells as indicated.
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by poly-APS result in loss of cell surface glycoproteins and
cell-cell interactions. 
In vivo effects of poly-APS. Due to the absence of lethal effects
of poly-APS on normal cells in vitro, we assayed them also
in vivo to investigate eventual organ toxicity. Intravenous
injection at two different doses (0.5 and 1 mg/kg) of poly-APS
with heparin did not cause any macroscopic toxic effects on
the mice. No weight loss in the treated mice was observed,
and no toxic effects, such as diarrhea, infection, weakening
or obvious behavioral changes, were detected. Subsequent
autopsy and histological analyses of selected organs showed
that the organ morphology, both at the gross and cytological
levels, did not show differences from the controls (Fig. 6).
Discussion
Here we show that NSCLC cell lines and tissues express a
full range of cholinergic molecules indicating that a functional
cholinergic signaling system is present in these cells. In cultured
A549 cells, the ChAT immuno-reactivity appeared mainly
intracytoplasmic, with a distribution gradient from the peri-
nuclear to the peripheral region, except for some focal points
of cell contact. For these molecules, as according to a recent
classification, membrane localization is typical of the neuronal
system, while the localization within the cytoplasm is typical
for non-neuronal cells (20). Moreover, it is known from the
literature that the localization at the cell membrane is one of
the conditions for ChAT biosynthetic activity (21), which is
regulated by interaction with other proteins related to the
cholinergic membrane (22).
Neurotransmission depends on the regulated exocytotic
release of chemical transmitter molecules. This requires the
packaging of these substances into the specialized secretory
vesicles of neurons and neuroendocrine cells, a process
mediated by specific vesicular transporters (23). The vesicular
ACh transporter (VAChT) is the protein that transports acetyl-
choline into synaptic vesicles for regulated exocytotic release
(24). The presence of this molecule in both NSCLC samples
and cell lines demonstrates an active function of ACh in this
tumor type. Moreover, in A549 cells, the immuno-reaction
reveals that vesicles are localized in the cytoplasm periphery
and under the cell membrane, showing an active exocitosis of
the neurotransmitter. The synthesis and secretion of ACh is
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Figure 6. Histological analyses (H&E) of the major organs for detecting organ toxicity in C57/BL mice: heart (a and b), liver (c and d) and kidney (e and f)
respectively treated and untreated with poly-APS salts.
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compensated by the presence of the lytic enzyme, AChE,
even if ChAT appears to be expressed at higher levels than
AChE. In fact, immuno-reactivity and Western blot analysis
show higher expression of the synthetic enzyme. Finally, the
cells were positive of the membrane receptors of this system,
indicating a potential tightly-regulated autocrine loop.
Polymeric alkylpiridinium salts, extracted from the sponge,
Reniera sarai, exert a strong inhibition of AChE, the lytic
enzyme of the cholinergic system (14). The presence of cholin-
ergic molecules in NSCLC led us to hypothesize that poly-APS
could exert possible effects. Poly-APS showed significant
NSCLC selective cytotoxicity, where it appeared to induce
rapid apoptosis, but was tolerated well by normal cells. To
verify the lack of toxicity and the eventual secondary effects
of the compound, we injected two different doses of poly-
APS intravenously (through the caudal vein) into C57/BL
mice. No variations regarding animal weight or macroscopic
effects, such as diarrhea, infection, weakening and behavioral
alterations, with respect to controls, were observed. Moreover,
histological analysis of selected organs that are typical targets
of toxic agents showed identical histology with controls.
Malignant transformation is associated with abnormal
glycosylation, resulting in the synthesis and expression of
altered carbohydrate moieties (19). These recent results have
confirmed that these determinants are not merely markers
for cancer, but are functionally implicated in the malignant
behavior of cancer cells and may be an inevitable consequence
of the malignant transformation of cells. We observed that
poly-APS interferes with cell-cell adhesion in the suspension
culture and alters cell surface glycosylation patterns as assessed
by decreased staining with Con-A and WGA lectins. 
Our data suggest that the cholinergic system may be an
important component of growth regulation in lung cancer,
and that interruption of this system through an AChE inhibitor
results in selective induction of apoptosis in lung cancer
cells. Irinotecan, a camptothecin derivative inhibitor of topo-
isomerase I that is used in lung cancer treatment and therapy,
is also able to inhibit AChE activity (25,26). It is possible that
some of the effects of Irinotecan on lung cancer may be due
to its ability to inhibit AChE, and selective AChE inhibition
may show effectiveness with less toxicity. The apparent lack
of toxicity for normal cells in vitro and normal tissues in vivo
of the poly-APS AChE inhibitor, coupled with its strong
toxicity for NSCLC cells, indicates that this molecule may be
a new and innovative chemotherapeutic agent.
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